Medicenna Therapeutics (TSXV: MDNA) CEO: Our Drug Has Potential for Phase 2 Approval

Medicenna Therapeutics Corp. (TSXV: MDNA) President & CEO said the Company received a large grant from the state of Texas

In this interview with SmallCapPower at the Bloom Burton & Co. Healthcare Investor Conference, Medicenna Therapeutics Corp. (TSXV: MDNA) President & CEO Fahar Merchant talks about Medicenna’s clinical trials in developing a drug treatment for glioblastoma, the most aggressive and common form of brain cancer.

Disclosure: Neither any of the principals at Small Cap Power, nor their family members, own shares in any of the companies mentioned above.

The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. To read more of this Disclaimer please click on the button below: